Close Menu

influenza

Technology partners on the study include BioMérieux and SkylineDx, as well as Imperial College London's biomedical electronics unit.

The researchers are studying use of pharmacy testing to monitor hypertension and cholesterol as well as for detecting and managing various infectious diseases.

A recent study established high sensitivity and specificity for three CLIA waived point-of-care molecular flu tests in pediatric samples.

The firm is developing the test under a contract with the US Department of Health and Human Services' Biomedical Advanced Research and Development Authority.

The firm saw a 36 percent increase in influenza product sales compared to the third quarter last year.

Cambridge, UK-based Sense Biodetection will use the funding to develop a portfolio of instrument-free, point-of-care molecular diagnostic tests.

The test is the latest in a series of CE-IVD-marked assays the company has launched for use on Becton Dickinson's PCR-based BD Max platform.

Investigators at the Foundation for Research and Technology - Hellas, a Greek research institute, are coordinating the effort.

The company's Acucy Influenza A&B test detects viral nucleoprotein antigens from nasal and nasopharyngeal swabs. 

Beyond its HostDx Sepsis test, the firm is working on a test to detect and differentiate bacterial from viral infections in patients presenting with fever.

Pages